A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say

A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.

By Alexandra Pecci • Sept. 12, 2023

Ex-Sanofi executive Sibold joins Madrigal as new CEO

Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.

By Ned Pagliarulo • Sept. 11, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

By Michael Gibney • Sept. 7, 2023

Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Lawmakers are already gunning for more dramatic drug pricing reforms

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

By Karissa Waddick • Aug. 31, 2023

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

By Karissa Waddick • Aug. 25, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Behind Flagship Pioneering’s triumphs and tribulations

From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

By Karissa Waddick • Aug. 18, 2023

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.

By Kelly Bilodeau • Aug. 14, 2023

Pharma’s rare disease rush

Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

By Meagan Parrish , Karissa Waddick • Aug. 14, 2023

5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

By Meagan Parrish • Aug. 11, 2023

Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.

By Michael Gibney • Aug. 10, 2023

Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

By Taren Grom and Meagan Parrish • Aug. 9, 2023

Pharma’s rocky love affair with oxytocin

Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.

By Kelly Bilodeau • Aug. 7, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023

A pioneering approach to biotherapeutic antibody discovery

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.

By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

Is the COVID-19 market crashing?

Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

By Meagan Parrish • Aug. 3, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023